Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Mak, Gannon C.K.; Cheng, Peter K.C.; Lau, Stephen S. Y.; Wong, Kitty K.Y.; Lau, CS; Lam, Edmund Wing Wo; Chan, RW; Tsang, Dnc

doi:10.1016/j.jcv.2020.104500

Cited by 454 publications

(500 citation statements)

References 2 publications

Supporting

Mentioning

458

Contrasting

Unclassified

Order By: Relevance

“…The BIOCREDIT COVID-19 Ag (RapdGEN Inc. Korea) kit was also tested as a reference method simultaneously. Virus concentrations in each dilution were estimated from cycle threshold (Ct) value as described [ 3 ].…”

Section: Methodsmentioning

confidence: 99%

“…From March 16, 2020 to August 15, 2020, respiratory specimens from COVID-19 patients collected by the Public Health Laboratory Services Branch (PHLSB) in Hong Kong were retrieved for this evaluation. All of the specimens were confirmed with SARS-CoV-2 infection by RT-PCR as described [ 3 ].…”

Section: Methodsmentioning

confidence: 99%

“…We previously evaluated a RAD kit for SARS-CoV-2 on May 2020 [ 3 ]. Since then, many new RAD kits are commercially available.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Mak

Lau

Wong

et al. 2020

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

Highlights We compared analytical sensitivity and clinical sensitivity for the three commercially available rapid antigen detection (RAD) kits for detection of SARS-CoV-2 virus. The three RAD kits varied 102 to 105 fold less sensitive than RT-PCR. Clinical sensitivity of RAD kits ranged from 22.9% to 71.4% for detecting respiratory specimens from COVID-19 patients. Understanding the clinical characteristics of different RAD kits can increase the likelihood of positive results.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Mak

Lau

Wong

et al. 2020

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…TFC-MS/MS has been used for high-throughput determination of several important clinical biomarkers, such as small metabolites and proteins 22,23 . The TurboFlow Cyclone-P HPLC 0.5 × 50 mm column used for turbulent flow chromatography was selected for its robustness while requiring lower flow rates to generate turbulence 9 . From the initial panel of eight selected peptides, the two most hydrophobic peptides, DGIIWVATEGALNTPK and IGMEVTPSGTWLTYTGAIK, yielded the best results in TFC coupled to triple quadrupole MS detection.…”

Section: Discussionmentioning

confidence: 99%

Fast and low-cost detection of SARS-CoV-2 peptides by tandem mass spectrometry in clinical samples

Cardozo

Lebkuchen

Okai

et al. 2020

Preprint

View full text Add to dashboard Cite

The current outbreak of severe acute respiratory syndrome associated with coronavirus 2 (SARS-CoV-2) is pressing public health systems around the world, and large population testing is a key step to control this pandemic disease. Real-time reverse-transcription PCR (real-time RT-PCR) is the gold standard test for virus detection but the soaring demand for this test resulted in shortage of reagents and instruments, severely limiting its applicability to large-scale screening. To be used either as an alternative, or as a complement, to real-time RT-PCR testing, we developed a high-throughput targeted proteomics assay to detect SARS-CoV-2 proteins directly from clinical respiratory tract samples. Sample preparation was fully automated by using a modified magnetic particle-based proteomics approach implemented on a robotic liquid handler, enabling a fast processing of samples. The use of turbulent flow chromatography included four times multiplexed on-line sample cleanup and UPLC separation. MS/MS detection of three peptides from SARS-CoV-2 nucleoprotein and a 15N-labeled internal global standard was achieved within 2.5 min, enabling the analysis of more than 500 samples per day. The method was validated using 562 specimens previously analyzed by real-time RT-PCR and was able to detect over 83% of positive cases. No interference was found with samples from common respiratory viruses, including other coronaviruses (NL63, OC43, HKU1, and 229E). The strategy here presented has high sample stability and low cost and should be considered as an option to large population testing.

show abstract

“…Antigen tests are recently being introduced as a rapid diagnostic tool to screen community spread of the pandemic [ 25 ]. Limit of Detection (LoD) for antigen tests tend to be higher than that of nucleic acid amplification (NAA) [ 26 ]. Despite the questions regarding the sensitivity, among the currently available methods, lateral flow antigen tests are the fastest and can be performed by any healthcare professional without additional training [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World

Augustine

Das

Hasan

et al. 2020

JCM

View full text Add to dashboard Cite

The aggressive outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as COVID-19 (coronavirus disease-2019) pandemic demands rapid and simplified testing tools for its effective management. Increased mass testing and surveillance are crucial for controlling the disease spread, obtaining better pandemic statistics, and developing realistic epidemiological models. Despite the advantages of nucleic acid- and antigen-based tests such as accuracy, specificity, and non-invasive approaches of sample collection, they can only detect active infections. Antibodies (immunoglobulins) are produced by the host immune system within a few days after infection and persist in the blood for at least several weeks after infection resolution. Antibody-based tests have provided a substitute and effective method of ultra-rapid detection for multiple contagious disease outbreaks in the past, including viral diseases such as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Thus, although not highly suitable for early diagnosis, antibody-based methods can be utilized to detect past infections hidden in the population, including asymptomatic ones. In an active community spread scenario of a disease that can provide a bigger window for mass detections and a practical approach for continuous surveillance. These factors encouraged researchers to investigate means of improving antibody-based rapid tests and employ them as reliable, reproducible, sensitive, specific, and economic tools for COVID-19 mass testing and surveillance. The development and integration of such immunoglobulin-based tests can transform the pandemic diagnosis by moving the same out of the clinics and laboratories into community testing sites and homes. This review discusses the principle, technology, and strategies being used in antibody-based testing at present. It also underlines the immense prospect of immunoglobulin-based testing and the efficacy of repeated planned deployment in pandemic management and post-pandemic sustainable screenings globally.

show abstract

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Cited by 454 publications

References 2 publications

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Fast and low-cost detection of SARS-CoV-2 peptides by tandem mass spectrometry in clinical samples

Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World

Contact Info

Product

Resources

About